ATE494008T1 - Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen - Google Patents

Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen

Info

Publication number
ATE494008T1
ATE494008T1 AT07730142T AT07730142T ATE494008T1 AT E494008 T1 ATE494008 T1 AT E494008T1 AT 07730142 T AT07730142 T AT 07730142T AT 07730142 T AT07730142 T AT 07730142T AT E494008 T1 ATE494008 T1 AT E494008T1
Authority
AT
Austria
Prior art keywords
kinase inhibitor
psychiatric diseases
treat psychiatric
treat
diseases
Prior art date
Application number
AT07730142T
Other languages
English (en)
Inventor
Mauro Corsi
Isidore Faiferman
Pich Emilio Merlo
Emiliangelo Ratti
Paul Wren
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Application granted granted Critical
Publication of ATE494008T1 publication Critical patent/ATE494008T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT07730142T 2006-06-16 2007-06-13 Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen ATE494008T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0612026.5A GB0612026D0 (en) 2006-06-16 2006-06-16 New use
PCT/EP2007/055858 WO2007144390A1 (en) 2006-06-16 2007-06-13 Use of a p38 kinase inhibitor for treating psychiatric disorders

Publications (1)

Publication Number Publication Date
ATE494008T1 true ATE494008T1 (de) 2011-01-15

Family

ID=36775828

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07730142T ATE494008T1 (de) 2006-06-16 2007-06-13 Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen

Country Status (13)

Country Link
US (1) US7989479B2 (de)
EP (1) EP2029139B1 (de)
JP (1) JP2010528980A (de)
KR (1) KR20090020703A (de)
CN (1) CN101500567B (de)
AT (1) ATE494008T1 (de)
AU (1) AU2007259224A1 (de)
CA (1) CA2657390A1 (de)
DE (1) DE602007011756D1 (de)
EA (1) EA015483B1 (de)
ES (1) ES2358931T3 (de)
GB (1) GB0612026D0 (de)
WO (1) WO2007144390A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE375980T1 (de) * 2002-02-12 2007-11-15 Smithkline Beecham Corp Nicotinamide und deren verwendung als p38 inhibitoren
CN102633715B (zh) * 2012-03-23 2014-03-26 无锡爱内特营养保健品科技有限公司 一种丝裂原蛋白激酶p38的抑制剂及其制备方法
CA2917277A1 (en) * 2013-07-10 2015-01-15 Glaxosmithkline Intellectual Property (No.2) Limited Losmapimod for use in treating glomerular disease
BR112020006677A2 (pt) 2017-10-05 2020-10-06 Fulcrum Therapeutics, Inc. uso de inibidores p38 para reduzir a expressão de dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US20200297696A1 (en) * 2017-11-21 2020-09-24 Saint Louis University P38 inhibitors for the treatment of fshd

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2260033T3 (es) * 1999-07-02 2006-11-01 Stuart A. Lipton Uso de los inhibidores p38 mapk en efermadades oftalmicas.
GB0124939D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124932D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
ATE375980T1 (de) 2002-02-12 2007-11-15 Smithkline Beecham Corp Nicotinamide und deren verwendung als p38 inhibitoren
GB0209891D0 (en) 2002-04-30 2002-06-05 Glaxo Group Ltd Novel compounds
JP2005530788A (ja) * 2002-05-13 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド フェニル置換イミダゾピリジン類およびフェニル置換ベンズイミダゾール類
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308201D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0318814D0 (en) 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
GB0402140D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402138D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
AU2005264453B2 (en) * 2004-07-16 2011-07-14 Atsuo Sekiyama IL-18 receptor antagonist and pharmaceutical composition containing the antagonist
US20080051416A1 (en) 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
GB0512429D0 (en) 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
EP2034838A4 (de) 2006-06-16 2012-01-04 Glaxo Group Ltd Neuartige verbindungen
US20090318424A1 (en) 2006-06-16 2009-12-24 Mauro Corsi Novel compounds
EP2031965A4 (de) 2006-06-16 2010-06-30 Glaxo Group Ltd Neuartige verbindungen

Also Published As

Publication number Publication date
EA015483B1 (ru) 2011-08-30
WO2007144390A1 (en) 2007-12-21
AU2007259224A1 (en) 2007-12-21
KR20090020703A (ko) 2009-02-26
US20100016377A1 (en) 2010-01-21
DE602007011756D1 (de) 2011-02-17
CN101500567A (zh) 2009-08-05
CN101500567B (zh) 2012-05-16
EP2029139B1 (de) 2011-01-05
GB0612026D0 (en) 2006-07-26
JP2010528980A (ja) 2010-08-26
CA2657390A1 (en) 2007-12-21
EP2029139A1 (de) 2009-03-04
ES2358931T3 (es) 2011-05-16
US7989479B2 (en) 2011-08-02
EA200900034A1 (ru) 2009-06-30

Similar Documents

Publication Publication Date Title
MX2009006195A (es) Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi)piri midina y metodos de su uso.
ATE416177T1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE406351T1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
ATE517896T1 (de) P38-kinase-inhibitoren
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
UA92503C2 (ru) Соединения 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенного пиридина для лечения неврологических, психиатрических или болевых расстройств
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
MY148851A (en) Dihydropyridine derivatives as useful as protein kinase inhibitors
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
CY1108230T1 (el) Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
ATE521608T1 (de) Glucokinaseaktivatoren
ATE438404T1 (de) Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien
NO20071378L (no) Tiazolo-naftylsyrer.
BRPI0517435A (pt) triazóis úteis como inibidores de proteìna cinase
PH12012502070A1 (en) Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders
ATE494008T1 (de) Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen
ATE542536T1 (de) 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen
EA200701995A1 (ru) Способы уменьшения кальцификации
ATE424208T1 (de) Proteinkinaseinhibitoren
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties